MarketPulse

generalized myasthenia gravis

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Muscular Dystrophy Association

FDA Expands VYVGART Approval to All Generalized Myasthenia Gravis Patients

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.
ARGXFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Myasthenia Gravis Market Poised for Transformation With 8 Late-Stage Drug Candidates

Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.
NVSAZNREGNMKKGYROIV+3clinical trialsautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy